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Mutations of the p53 gene are the most common genetic 
abnormality described in human cancer; p53 mutations have 
recently been reported in more than half of the cases of squa-
mous cell carcinomas of the skin. We have previously re-
ported positive p53 immunostaining in Bowen's disease and 
actinic keratosis. To determine if this abnormal immuno-
staining reflects p53 mutation or alternative pathways of p53 
protein inactivation we h'ave performed direct sequencing of 
p53 in 20 further cases of Bowen's disease. We found eight 
T he p53 gene codes for a 53-kD phosphoprotein that can act as a negative regulator of cell proliferation. p53 is thought to be important in limiting cellular DNA damage following exposure to noxious stimuli such as ultraviolet radiation (UVR). Exposure to 
UVR increases p53 protein expression by post-translational mecha-
nisms that in turn block the cells in the G 1 IS step of the cell cycle, 
allowing vital DNA repair to take place before DNA replication 
occurs prior to the onset of mitosis [1-3]. 
Abnormalities of p53 in cancer cells have been demonstrated 
using immunocytochemistry or by direct sequencing of genomic or 
c-DNAs. Many mutations of the p53 coding region produce a func-
tionally inactive protein with a significantly prolonged half-life that 
is detectable by immunocytochemical techniques. Wild-type pro-
tein is either not detectable or only just detectable in normal resting 
cells [1]. Although detection of p53 in cells by immunocytochemis-
try techniques is suggestive of p53 mutation, recent work clearly 
shows there are alternative pathways for inactivation of wild-type 
p53 function that do not involve coding region mutations: the in-
crease in detectable p53 protein in these cases may reflect mutations 
outside the coding region, changes in other proteins that affect the 
half-life of p53, or even possibly abnormal phosphorylation of the 
protein [4]. Abnormalities of p53 function are common in human 
cancers [1] and p53 mutations have recently been described in up to 
half the cases of squamous cell carcinomas and basal cell carcinomas 
(BCCs) studied [5 - 7]. Studies of other human epithelial neoplasms 
have concentrated on describing mutations in invasive malignancy, 
although there are reports of positive immunostaining in squamous 
dysplasia of the oral mucosa (quoted in [8]) and in a subset of colonic 
polyps that were thought to be premalignant [9]. Recently, in a 
study of radon-associated lung cancer, Vahakangas et af [10] per-
formed microdissection of two separate foci around one invasive 
tumor consisting of preinvasive and microinvasive tumors, respec-
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mutations in 20 cases, seven of which would produce alter-
ations in the p53 protein product. Our results suggest that 
p53 mutation is an early event in malignant conversion, fre-
quently preceding invasion in squamous cell neoplasia of the 
skin. The type and site of the observed mutations reflect 
known mutational hotspots and support the role of ultravio-
let radiation in the pathogenesis of these tumors. ] Invest 
DermatoltOO:746-748, 1993 
tively. Immunostaining and direct sequencing revealed the same 
mutant form of p53 in all three samples. The authors argued that 
two hypotheses were compatible with this finding: p53 mutation 
occurs late in tumor development and tumor cells spread laterally 
within the mucosa away from the tumor, in which case preinvasive 
tumors will show most of the genetic abnormalities detected in 
invasive neoplasia; alternatively p53 mutation occurs early, the mu-
tation conferring a growth advantage, and tumor cells spread later-
ally until additional changes cause invasion, with late genetic 
changes being absent from the preinvasive lesion. Vogelstein's 
group has, however, shown that clonal expansion of cells with 
mutated p53 is associated with progression from low-grade to high-
grade astrocytomas; biopsies from tumor recurrences showed 
higher proportions of p53 mutations than biopsies at presentation 
[11] . This and other work has suggested that during tumor develop-
ment "stress" due to factors such as anoxia or aneuploidy would 
normally be expected to increase p53 expression, which in turn 
would limit cellular growth [2]; mutations that at this stage inacti-
vated p53 would allow tumor progression and would therefore be 
positively selected for. 
Human skin neoplasms provide a powerful system in which to 
explore and test some of these hypotheses. In particular, the pres-
ence of preinvasive lesions such as Bowen's disease allows examina-
tion of when during the course of multistage carcinogenesis muta-
tion or inactivation of p53 occurs. Bowen's disease is characterized 
clinically by red scaly plaques that show intraepithelial carcinoma 
on histologic examination. Bowen's disease shows a significant rate 
of progression to invasive squamous cell carcinoma (reported to be 
up 5%), although because of the widespread availability of effective 
therapy the figure may in reality be much higher [12] . 
We have previously reported that up to one third of cases of BD 
show positive immunostaining for p53 [13]; similar results have 
been reported by others [14]. If this positive immunostaining re-
flects p53 mutation then p53 mutation antecedes tumor invasion, 
and can be considered an early event in the development of squa-
mous cell neoplasia. Alternatively, absence of p53 mutation at this 
stage would suggest that alternative (nonmutational) pathways of 
p53 inactivation may be important in the development and progres-
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. n CO squamous cell carcinoma of the skin. To examine these 
!h10 ocheses we have carried out direct genomic sequencing of p53 in 
YP • d· 20 cases of :Bowen s Isease. 
MATERIALS AND METHODS 
Patients and ~amples Twenty tumor samples from 18 patients 
e studied. Fifteen of the patients were female and three male. ;c~een of the Bowen's lesions were from the leg, two of the lesions 
l"re from the hand or wrist, and two were Bowenoid actinic kera-
wCes fronL the face; all except one were from sun-exposed sites. ~ssed on history the mean duration of the lesions was 2 years. 
S 3mples w-ere collected prospectively and tumor was dissected free 
of apparently c1inical!y normal skin. Histologic examination con-
firmed the diagnosIs III all cases. 
E"traction of DNA Samples were snap frozen and stored at 
_700C: DNA was isolated by overnight digestion with proteinase 
f{ at 0.1 mg/ml and 0.2% sodium dodecyl sulphate at 50°C DNA 
rccipitated with isopropanol, and resuspended in TE (10 mM of 
h is-Hcl, 0.1 mM ethylenediaminetetraacetic acid, pH 7.5) [15]. 
polytnerase Chain Re~ction PCR was ~arried out using stan-
dtId conditions. One mIcrogram of genomIC DNA and S3 ng of 
3ch of the two primers were added to a reaction mixture containing 
~ 5 units ofTaq DNA polymerase (NBL, UK), 10 mM Tris-HCl, 
frB. B, 50 mMKCI,1.5mMMgCI2 ,0.1%Triton-X-100,and2.0 ~ dNT~s, to a final v.olume of 100 ,ul. Reaction samples v:ere 
overlaid WIth 50 pi of mllleral 011 (Sigma) to prevent evaporation. 
primers used were as follows: 
e)Con 5: 5' GGATCCATCTGTTCACTTGTGCCCTG 3' 
5'GAATTCAACCAGCCCTGTCGTCTCTC3' 
(biotinylated) 
e)Con 6: 5' GGAGGGCCACTGACAACC 3' 
5' GCCTCTGATTCCTCACTGAT 3' (biotinylated) 
eXon 7: 5' GAATTCAGGGGTCAGCGGCAAGCAGA 3' 
5'GGATCCAGGCGCACTGGCCTCATCTT3' 
(biotinylated) 
e)Con 8: 5' GGACCTGATTTCCTTACTGC 3' 
5' TTTGGCTGGGGAGAGGAGCT 3' (biotinylated). 
DNA was amplified for 40 cycles (1 min at 9S DC, 1 min at 55°C, 1 
JIlin at 72 0 C) in an automated DNA thermal cycler (Perkin-Elmer 
CetuS). 
Sequencing Polymerase chain reaction (PCR) products were pu-
rined on 2% Nusieve gels and DNA isolated from the excised bands 
by incubation for 60 min at 65 °C witl~ 16 pI of streptavidin-coated 
magnetic beads (Dynal, UK). The Single-stranded template, ob-
tained according to manufacturer's instructions, was sequenced by 
che dideoxy-termination method using the unbiotinylated PCR 
primer (15 ng), (35S). dATP, and Sequenase version 2.0 (U.SB). All 
positives were amplified from tumor ~NA on two occasIOns and 
mutation confirmed by repeat sequencmg. Samples from non-le-
sional skin and from control individuals were sequenced in parallel 
to ensure that the reported changes did not represent p53 polymor-
pnisms, germline mutations, or technical artefacts. 
RESULTS 
All exons in all samples ampl ified under the conditions described. 
Sequencing of the PCR products revealed eight n~utations (Table I). 
Seven of these mutatIOns would have resulted 111 a change in the 
amino acid sequence of the p53 protein and one would have been 
silent; one introduced a premature stop codon resulting in a trun-
cated protein. Mutations at codons 248 and 273 were noted and five 
of the eight mutations were in known mutational hotspots (Fig 1) 
~ee Vogel stein and Kinzier [2)). None of the tumors contained 
CC~TT double base changes that are specific for UV -induced 
mutagenesis [5]. Six of the eight observed changes occurred at di-
pyrimidine sites. Five of these ~utations IJroduced a C~T transi-
tion. C~T mutatIOns at CG sItes II1dlca[Jve of mutatIOns due to 
spontaneously deaminated 5-methyl-cytosine were not detected. 
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DISCUSSION 
Using direct sequencing of PCR products we have identified eight 
mutations of the p53 coding region in 20 cases of Bowen's disease; 
one was silent and in one individual two different mutations were 
identified. Samples were collected prospectively and were clinically 
and histologically typical of Bowen's disease. Most of the lesions 
were from sun-exposed sites. The results show that pS3 mutation is 
a common and early event in the development of squamous cel l 
neoplasia of the skin; mutation frequently precedes tumor invasion. 
The proportion of mutations detected in Bowen's disease in this 
study does not differ significantly from those reported by Brash et at 
[5] for cutaneous squamous cell carcinomas from a European popula-
tion and is greater than that of Pier call et al in squamous cell carcino-
mas [7]. Although the populations examined were different. these 
data taken together imply that if p53 mutation is going to occur it 
occurs early during tumor development. Five of the eight mutations 
in our study occurred in known mutational hotspots including 
codons 248 and 273. The spectrum of observed mutations in the 
cases of Bowen's disease was different from those observed by Brash 
et at (5) in squamous cell carcinomas from sun-exposed skin. Al-
though we found no CC~TT double base changes, six of eight 
mutations occurred at pyrimidine dimer sites with C~T transitions 
predominating. This pattern of mutation suggests that the initial 
mutagenic lesion in the p53 gene in these lesions was a dipyrimidine 
photoproduct induced by UVR. 
The proportion of lesions we found showing p53 mutations on 
sequencing is similar to that we have reported as showing abnormal 
p53 immunostaining in another series of cases of Bowen's disease 
(13). However, because we were unable to perform both techniques 
on the same samples it cannot be assumed that both reflect the same 
pathologic process. There is increasing evidence that inactivation of 
p53 may be due to either coding region mutation or abnormalities of 
p53 expression secondary to altered p53 metabolism or binding of 
other proteins to p53 [2,4] . Recent reports suggest that in up to 40% 
o~ cases there may be positive immunostaining without mutation or 
vice versa [10]. Our results show that p53 mutation accounts for a 
substantial number of cases of abnormalities of p53. Our results are 
likely to underestimate the proportion with p53 mutations for two 
reasons. Firstly, inevitable mixing of normal and tumOr cells in the 
samples studied will reduce the sensitivity of detection of mutant 
atlele, ~nd secondly we have only sequenced the conserved regions 
(mutations may occur outside the conserved regions but in other 
tumor types are uncommon (2)). 
Our results suggest that the role of p53 mutation in squamous cell 
carcmoma of the skin is different from that seen in colonic cancer 
~here mutation rarely precedes invasion [9). Although the clinical 
tIme cours~ of progression from Bowen's disease to squamous cell 
carcmoma IS unclear, it is, we believe, unlikely that all the samples 
we found to .be positive were undergoing imminent progression to 
mvaSlve malignancy. Because we have observed very similar nuclear 
positive immunostaining in Bowen's disease and actinic keratoses 
we believe thatf53 mutation is an important and early event in the 
development 0 squamous cell carcinoma of the skin. Although 
contamination of wild type alleles may make examination of small 
actinic keratoses difficult, the highly variable natural history of 
Tumor 
65 
126 
137 
115 
142 
13 
48 
115 
Table I. Summary of p53 Gene Mutations 
in 20 Cases of Bowen's Disease 
Codon 
192 
248 
250 
265 
273 
273 
278 
286 
Base Change 
C-T 
C--T 
C-T 
T-C 
G->T 
G-T 
C-T 
G-+A 
Amino Acid Change 
GIn -> seop 
Arg ->Trp 
Pro -- Pro 
Leu ->Pro 
Arg -+ Leu 
Arg -+ Leu 
Pro -+ Ser 
GIu ..... Lys 
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Figure 1. (a) Tumour DNA, showing C-+T transition at codon 248 (*). (b) 
Normal sequence at codon 248 (*). 
actinic keratoses and the response of many of these lesions to chemo-
therapeutic agents such as retinoids makes the further molecular 
delineation of these early events important. 
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